COMMUNIQUÉS West-GlobeNewswire

ONWARD Medical Reports First Half 2026 Results with Strong Product Revenue Growth and Continued Progress across ARC Therapy Pipeline
09/09/2026
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
09/09/2026
BEIJING, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
ICG-21 Opens in Shenzhen, Spotlighting Bio-Generative Intelligence for Health and New Frontiers in Genomics
09/09/2026
SHENZHEN, China, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The 21st Annual Meeting of the International Conference on Genomics (ICG-21) was held at the BGI Center in Shenzhen from September 7 to 8. Under the theme “Bio- [...]
XORTX Re-Engages Investor Relations Program
09/09/2026
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture [...]
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09/2026
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the [...]
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
08/09/2026
Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in [...]
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
08/09/2026
TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q [...]
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
08/09/2026
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo ® (berotralstat), a plasma kallikrein [...]
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
08/09/2026
U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28,   2027 If approved, Oxnimbi has the potential to [...]
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
08/09/2026
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H. [...]
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
08/09/2026
NEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) announced today that it received written confirmation from the Listing [...]
New meta-analysis shows statistically significant improvements in patient outcomes associated with da Vinci surgery versus laparoscopic and open surgery across 13 common benign conditions
08/09/2026
Largest comparative meta-analysis of its kind found da Vinci robotic-assisted surgery was associated with shorter hospital stays and a faster return to work compared with laparoscopic and open surgery SUNNYVALE, Calif [...]
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
08/09/2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics [...]
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
InnovAge Announces Financial Results for the Fourth Quarter and Fiscal Year Ended June 30, 2026
08/09/2026
DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Journey Medical Corporation to Participate in September 2026 Investor Conferences
08/09/2026
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and [...]
Carlsmed, Inc. Announces Chief Operating Officer Appointment
08/09/2026
CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced [...]
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
08/09/2026
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the [...]
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
08/09/2026
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart [...]

Pages